Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease - Summary - MDSpire

Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease

  • By

  • Sarah E. Polk

  • Lindsay R. Clark

  • Kristin Basche

  • Luca Kleineidam

  • Wenzel Glanz

  • Michaela Butryn

  • Robert Perneczky

  • Katharina Buerger

  • Klaus Fliessbach

  • Christoph Laske

  • Annika Spottke

  • Anja Schneider

  • Jens Wiltfang

  • Stefan Teipel

  • Claudia Bartels

  • Ayda Rostamzadeh

  • Daniel Janowitz

  • Boris-Stephan Rauchmann

  • Ingo Kilimann

  • Sebastian Sodenkamp

  • Marie Coenjaerts

  • Frederic Brosseron

  • Michael Wagner

  • Ingo Frommann

  • Melina Stark

  • Matthias Schmid

  • Björn H. Schott

  • Sterling C. Johnson

  • Frank Jessen

  • Emrah Düzel

  • David Berron

  • June 10, 2026

Share

Objective:

To evaluate the effectiveness of remote digital cognitive assessments in detecting early memory impairment in prodromal Alzheimer's disease.

Key Findings:
  • The MCI group exhibited greater cognitive decline than the CU group in familiarity-dependent tasks (p < 0.05).
  • MCI participants with beta-amyloid (Aβ+) showed more significant changes in memory precision and familiarity-dependent memory (p < 0.01).
  • A 30-week change in remote familiarity-dependent tasks correlated with multi-year changes in in-person neuropsychological assessments (r = 0.75, p < 0.01).
Interpretation:

Frequent remote cognitive testing can effectively capture subtle cognitive decline in early Alzheimer's disease.

Limitations:
  • The study's sample size may limit generalizability.
  • The reliance on self-administered tasks may introduce variability in data quality.
  • Potential bias in self-reported data could affect the reliability of cognitive assessments.
Conclusion:

Remote digital cognitive assessments are promising tools for monitoring cognitive decline in early Alzheimer's disease.

Original Source(s)

Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease

  • by Sarah E. Polk, Lindsay R. Clark, Kristin Basche, Luca Kleineidam, Wenzel Glanz, Michaela Butryn, Robert Perneczky, Katharina Buerger, Klaus Fliessbach, Christoph Laske, Annika Spottke, Anja Schneider, Jens Wiltfang, Stefan Teipel, Claudia Bartels, Ayda Rostamzadeh, Daniel Janowitz, Boris-Stephan Rauchmann, Ingo Kilimann, Sebastian Sodenkamp, Marie Coenjaerts, Frederic Brosseron, Michael Wagner, Ingo Frommann, Melina Stark, Matthias Schmid, Björn H. Schott, Sterling C. Johnson, Frank Jessen, Emrah Düzel, David Berron

  • June 10, 2026

Related Content

ARPA-H Launches New Program to Deliver Rigorous, Gold-Standard Research Faster

The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease